American Journal of Psychiatry Publishes Minerva Neurosciences' MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia
WALTHAM, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that the American Journal of Psychiatry has published online results from its previously reported Phase 2b clinical trial of MIN-101. MIN-101 is a novel compound with affinities for sigma2 and 5HT2A receptors but no direct activity on dopamine receptors. In this regard, MIN-101 differs from drugs currently indicated for schizophrenia, all of which directly interfere with dopamine neurotransmission by antagonizing dopamine receptors.
The manuscript, entitled "Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia," and be found online at http://www.medical-reprints.com/US-MN-AJP-Davidson.
The key finding from the publication is that MIN-101 achieved its primary outcome in the trial, demonstrating statistically significant superiority over placebo in improving negative symptoms in schizophrenia patients as measured by the pentagonal negative symptoms cluster of the Positive and Negative Syndrome Scale (PANSS). The improvement in negative symptoms was shown for both doses tested: 32 milligrams (mg): p = 0.024 effect size = 0.45, and 64 mg: p = 0.004 effect size = 0.57.
Supporting these findings were similar and concomitant improvements on several secondary outcome measures, including PANSS cluster analyses of negative symptoms, the PANSS total score, the Clinical Global Impression (CGI) and the Brief Negative Symptom Scale (BNSS). Psychosis measured by the PANSS Positive symptoms subscale remained stable during the trial, suggesting that the improvement in negative symptoms associated with MIN-101 was specific and not a pseudo-effect secondary to improvements in psychosis.
MIN-101 also demonstrated good tolerability, with no weight gain or other metabolic abnormalities, no clinically significant changes in vital signs, routine laboratory values, sedation and extra-pyramidal symptoms (EPS). The lack of observed adverse effects associated with MIN-101 treatment as compared to placebo helped to preserve the blinding of the trial, further supporting the validity and specificity of the improvement observed in negative symptoms.
"Negative symptoms, which tend to persist even after psychosis improves, are the main impediment to social reintegration of schizophrenia patients," said Dr. Philip D. Harvey, Leonard M. Miller Professor of Psychiatry and Director of the Division of Psychology at the University of Miami Miller School of Medicine and an expert in the rehabilitation of schizophrenia patients. "No drugs in the U.S. are currently indicated for negative symptoms in schizophrenia, and a drug with specific effects on negative symptoms has a real chance to improve the day-to-day social and vocational functioning of patients affected by this disease."
"The findings published in the American Journal of Psychiatry are noteworthy in that MIN-101 was shown to improve negative symptoms without blocking dopamine receptors, unlike other drugs indicated for schizophrenia," said Dr. Harvey. "As such, it may be better tolerated by patients and may improve drug adherence, which is particularly problematic in treating schizophrenia." Dr. Harvey was not involved in the design or the conduct of the Phase 2b trial with MIN-101.
"The publication of these data by a prestigious journal like the American Journal of Psychiatry is important for Minerva because it reflects a peer-reviewed recognition by the scientific and medical community of a new and innovative potential approach to alleviating the most debilitating symptoms in patients suffering from schizophrenia," said Dr. Remy Luthringer, president and chief executive officer of Minerva.
Following a recent "end-of-Phase 2" meeting with the U.S. Food and Drug Administration (FDA), Minerva expects to initiate a pivotal Phase 3 trial with MIN-101 to treat negative symptoms in schizophrenia in the second half of 2017.
About the American Journal of Psychiatry
The American Journal of Psychiatry is the official journal of the American Psychiatric Association (APA), the oldest medical association in the country, founded in 1844. It is published monthly and is focused on a broad spectrum of issues and advances in the diagnosis and treatment of mental illness. The APA is the largest psychiatric association in the world with more than 37,000 physician members specializing in the diagnosis, treatment, prevention and research of mental illness.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-202 (JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to: the timing and results of future clinical milestones with MIN-101, including the planned Phase 3 trial of MIN-101, the timing and scope of future clinical trials and results of clinical trials with this compound; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize MIN-101; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether MIN-101 will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether the results of future clinical trials of MIN-101, if any, will be consistent with the results of past clinical trials; whether MIN-101 will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management's ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, filed with the Securities and Exchange Commission on May 4, 2017. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
NTT Security Launches Security Services for Industrial Control Systems20.9.2017 10:00 | Pressemelding
Cyber-defense for critical infrastructure including factories, plants, utilities & hospitals TOKYO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- NTT Security Corporation (Head Office: Chiyoda-Ku, Tokyo; CEO: Jun Sawada), the specialized security company of NTT Group, has launched "IT/OT Integrated Security Services". The new services will be taken to market globally through the NTT Group companies, Dimension Data, NTT Communications and NTT DATA, forming part of its suite of integrated services to enable successful digital transformation initiatives for its clients. Companies are increasingly working towards IT/OT (Operational Technology) alignment. OT systems, when connected to the internet, streamline business operations by advanced supply chain management, realization of mass customization and improvement of customer experience as well as find new intelligence employing IoT (the Internet of Things) and Big Data analytics. As a result, IT/OT convergence is ex
NTT Security lanserer sikkerhetstjenester for industrielle kontrollsystemer20.9.2017 10:00 | Pressemelding
Cyberforsvar for kritisk infrastruktur, inkludert fabrikker, anlegg, forsyningstjenester og sykehus Oslo, 20. sept. 2017 (GLOBE NEWSWIRE) - NTT Security Corporation (hovedkontor: Chiyoda-Ku, Tokyo; adm.dir.: Jun Sawada), det spesialiserte sikkerhetsselskapet til NTT Group, har lansert IT/OT Integrated Security Services. De nye tjenestene skal markedsføres globalt gjennom NTT Group-selskapene Dimension Data, NTT Communications og NTT DATA. De inngår i en pakke med integrerte tjenester som gjør det mulig for kundene å gjennomføre digitale transformasjonsinitiativ. Selskaper arbeider i økende grad med tilpasning av IT/OT (operativ teknologi). Når OT-systemer kobles til internett, kan de effektivisere forretningsvirksomheten gjennom avansert styring av forsyningskjeden, realisering av massetilpasning og forbedring av kundeopplevelsen, samt utvikle ny intelligens som benytter IoT (Internet of Things, tingenes internett) og stordataanalyse. Som et resultat av dette gjør IT/OT-k
Zumio(TM) Now Available in Europe20.9.2017 08:00 | Pressemelding
Exclusive Partnership Agreement Signed with Eropartner Distribution Ottawa, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Zumio Inc. proudly announces it has partnered exclusively with Eropartner Distribution for distribution across all 28 EU member countries. Winner of the Best New Product at ADULTEX 2017, Zumio is the world's only clitoral stimulator based on the proven circular fingertip motion. Zumio's patented SpiroTIP(TM) and motor clutch drive system allows users to dynamically go from high speed and intensity down to a low speed and intensity, without having to touch a control, to instinctively and more naturally, adjust the stimulation to suit their needs. "Traditional vibrators generate excess energy and shake everything they touch often creating sensory overload and a numbing effect," said Steve Traplin, Chief Revenue Officer at Zumio. " Our non-vibrating technology makes Zumio more comfortable to hold and the small TIP and
Juniper Systems Limited Eyes German Market with InterGeo 2017 Exhibit, Opens New Office in Wels, Austria20.9.2017 04:16 | Pressemelding
BIRMINGHAM, United Kingdom, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Manufacturer of rugged handheld data collectors Juniper Systems Limited aims to expand its footprint in the German marketplace. Coinciding with the opening of its new office in Wels, Austria, the company will exhibit at the geometrics industry trade fair, InterGeo 2017, next week in Berlin, Germany. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ec8e4e2c-b277-48f9-bce9-4606d17454a5 The Wels location was recently opened to serve German-speaking partners and customers in Austria, Germany, and other Eastern European countries. Juniper Systems will showcase its ultra-rugged solutions for GIS, geomatics and geoinformation applications in Hall 1.1 on Stand C1.010 on 26 - 28 September at InterGeo. 'We're excited to be exhibiting at the InterGeo trade fair, which is now a regular date in our diary', commented Simon Bowe, general manager of Juni
CallidusCloud Unveils Game-Changing Augmented Intelligence Platform for Sales Performance, Execution and Learning Customers19.9.2017 22:35 | Pressemelding
Thunderbridge AI³ Combines the Power of Artificial Intelligence, Application Integration, and Human Insight to Provide Contextual Augmented Intelligence Recommendations throughout the Lead to Money suite DUBLIN, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, unveiled its newest platform, Thunderbridge Augmented Intelligence - or Thunderbridge AI³ - today at CallidusCloud Connections (C3) 2017, its annual user conference. The new solution is comprised of three elements: artificial intelligence, application integration, and human insight. The Thunderbridge Augmented Intelligence platform is a layer of software that applies machine learning techniques to the sales and learning processes to come up with recommended actions for increasing revenue, profit, and sales effectiveness. The role of human insight and behavior is key to Thunderbridge AI
Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress19.9.2017 22:05 | Pressemelding
Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress UTRECHT, The Netherlands, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced financial results for the second quarter ended June 30, 2017 and provided a corporate and clinical update. "Merus has had a productive year to date, marked by progress in our work with Incyte and our other collaborators, the presentation at ASCO of positive Phase 1/2 data for our lead candidate MCLA-128 in the first of several indications, and progress among a stable of very exciting Biclonics®-based bispecific antibody therapy candidates toward and through the clinic," said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. "We believe that the potential of Merus' Biclonics® platform, which holds a number of key advantages over other bispecific antibody a
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom